嬰兒痙攣症藥物市場規模、佔有率和成長分析（按療法、類型、劑量、給藥途徑、最終用戶、分銷管道和地區分類）—2026-2033年產業預測

預計到 2024 年，全球嬰兒痙攣症治療市場規模將達到 1.4924 億美元，到 2025 年將達到 1.5909 億美元，到 2033 年將達到 2.6528 億美元，預測期（2026-2033 年）的複合年成長率為 6.6%。

嬰兒痙攣症治療藥物的全球市場正經歷顯著成長，這主要得益於該疾病發病率的上升、人們對嬰兒痙攣症作為兒童疾病的認知不斷提高，以及政府對研發的大力支持。兒童神經病學基礎設施的擴建和藥物製劑的進步對於支持治療方法至關重要。此外，全球兒童神經病學專科服務的快速發展也有助於提高治療的可近性。先進的腦電圖（EEG）、磁振造影（MRI）和基因分析工具等技術進步，提升了嬰兒痙攣症的早期診斷能力。儘管公眾意識的提高以及政府醫療保健項目和非營利組織的大量資金支持推動了該市場的發展，但高昂的治療費用、缺乏訓練有素的專家、潛在的副作用以及某些地區診斷不足等挑戰仍然是限制市場成長的障礙。

推動全球嬰兒痙攣症藥物市場發展的因素

醫學界對嬰兒痙攣症的認知不斷提高，顯著提升了診斷和治療的速度和準確性。小兒科和全科醫生對嬰兒痙攣症的症狀和嚴重的了解不斷加深，使得疑似病例更快地轉診至專科醫生。這種臨床關注的提升不僅帶來了更即時的治療性介入，降低了長期神經發育障礙的風險，也促進了嬰兒痙攣症專科治療方法的普及。因此，這一趨勢正在推動全球嬰兒痙攣症治療市場的成長。

限制全球嬰兒痙攣藥物市場的因素

全球嬰兒痙攣症治療市場面臨許多挑戰，例如促腎上腺皮質激素（ACTH）和Vigabatrin等治療方法會帶來嚴重的副作用，如腎上腺抑制、視力障礙和免疫抑制。這些不良反應可能導致醫護人員和看護者在考慮治療方案時猶豫不決。此外，缺乏更安全的長期替代療法加劇了這個問題，可能導致治療中斷或患者放棄治療。這種猶豫會阻礙嬰兒痙攣症的有效治療，最終影響患者的治療效果和整體市場成長。

嬰兒痙攣症治療市場的全球趨勢

全球嬰兒痙攣症藥物市場正經歷著向精準醫療和基因分析的重大轉變，徹底改變了治療方法。基因檢測和次世代定序的日益普及，有助於識別嬰兒痙攣症的根本病因，從而實現個人化和標靶化治療。隨著分子診斷技術的進步，其可及性和可負擔性不斷提高，製藥公司正優先開發針對特定突變的標靶治療。這一趨勢不僅有望透過個人化治療改善患者預後，也凸顯了創新治療方案的潛力，從而推動嬰兒痙攣症治療領域的成長和變革。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

全球嬰兒痙攣症治療市場規模（按療法和複合年成長率分類）（2026-2033 年）

• 抗驚厥藥
• 皮質類固醇
• 其他

全球嬰兒痙攣症治療市場規模（按類型和複合年成長率分類）（2026-2033 年）

• Vigabatrin
• 促腎上腺皮質激素
• III期臨床試驗

全球嬰兒痙攣症治療市場規模（按劑量和複合年成長率分類）（2026-2033 年）

• 固態劑型
• 液體

全球嬰兒痙攣症治療市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 口服
• 腸外
• 其他

全球嬰兒痙攣症治療市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 診所
• 醫院
• 其他

全球嬰兒痙攣症治療市場規模（按分銷管道和複合年成長率分類）（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球嬰兒痙攣症治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Amneal Pharmaceuticals LLC（US）
• Cipla（India）
• Endo, Inc.（US）
• H. Lundbeck A/S（Denmark）
• Hetero（India）
• Intas Pharmaceuticals Ltd.（India）
• Jazz Pharmaceuticals, Inc.（Ireland）
• Mallinckrodt（Ireland）
• MSN Laboratories（India）
• Ovid Therapeutics（US）
• SGPharma Pvt. Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Zydus Group（India）
• Merz Therapeutics（US）
• Ionis Pharmaceuticals（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Eisai Co., Ltd.（Japan）

結論與建議

Global Infantile Spasms Therapeutics Market size was valued at USD 149.24 Million in 2024 and is poised to grow from USD 159.09 Million in 2025 to USD 265.28 Million by 2033, growing at a CAGR of 6.6% during the forecast period (2026-2033).

The global market for infantile spasms therapeutics is experiencing significant growth driven by an increase in the incidence of the condition, enhanced awareness of pediatric diseases, and robust governmental support for research and development efforts. The proliferation of pediatric neurology infrastructure and advancements in drug formulations are pivotal in bolstering therapeutic adoption. Moreover, the surge in specialized pediatric neurology services worldwide is enhancing access to treatments. Technological advancements such as sophisticated EEG, MRI, and genetic sequencing tools are improving early diagnostic capabilities for infantile spasms. While rising awareness and substantial funding from government healthcare programs and nonprofit organizations support this market, challenges such as high treatment costs, a shortage of trained specialists, potential side effects, and underdiagnosis in certain regions continue to pose barriers to market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infantile Spasms Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infantile Spasms Therapeutics Market Segments Analysis

Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infantile Spasms Therapeutics Market

The increasing awareness within the medical community regarding infantile spasms has significantly improved the speed and accuracy of diagnosis and treatment. Enhanced education among pediatricians and general practitioners about the symptoms and critical nature of these spasms has led to quicker referrals to specialists for suspected cases. This heightened level of clinical attention has resulted in more immediate therapeutic interventions, which not only mitigate the risk of long-term neurodevelopmental impairments but also promote greater utilization of treatments specifically designed for infantile spasms. Consequently, this trend is driving growth in the global market for infantile spasms therapeutics.

Restraints in the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market faces challenges due to the substantial side effects linked with treatments such as ACTH and vigabatrin, which include adrenal suppression, vision impairment, and immune suppression. These adverse effects can create reluctance among healthcare professionals and caregivers when considering treatment options. Furthermore, the lack of safer long-term alternatives exacerbates this issue, potentially leading to discontinuation or avoidance of treatment in some cases. This hesitation can hinder the effective management of infantile spasms, ultimately impacting patient outcomes and the overall growth of the market.

Market Trends of the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market is witnessing a significant shift towards precision medicine and genetic profiling, which is revolutionizing treatment approaches. Increasing utilization of genetic testing and next-generation sequencing facilitates the identification of underlying causes of infantile spasms, enabling personalized and targeted interventions. As advancements in molecular diagnostics enhance accessibility and affordability, pharmaceutical companies are prioritizing the development of mutation-targeted therapies. This trend not only promises improved patient outcomes through tailored treatments but also underscores the potential for innovative therapeutic solutions, driving growth and transformation within the infantile spasms therapeutics landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Infantile Spasms Therapeutics Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Anticonvulsants
• Corticosteroids
• Others

Global Infantile Spasms Therapeutics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Vigabatrin
• Adrenocorticotropic Hormone
• Phase III

Global Infantile Spasms Therapeutics Market Size by Dosage & CAGR (2026-2033)

• Market Overview
• Solid
• Liquid

Global Infantile Spasms Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Others

Global Infantile Spasms Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Clinic
• Hospital
• Others

Global Infantile Spasms Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Infantile Spasms Therapeutics Market Size & CAGR (2026-2033)

• North America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amneal Pharmaceuticals LLC (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals, Inc. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGPharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merz Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations